Prevalence of Musculoskeletal Manifestations in Adult Kidney Transplant’s Recipients: A Systematic Review
Abstract
:1. Introduction
2. Materials and Methods
2.1. Data Search
2.2. Study Eligibility Criteria
3. Results
4. Discussion
4.1. Discussion of the Studies Included in This Review: Bone Pain Syndrome (BPS)
4.2. Discussion of the Studies Included in This Review: Hyperuricemia (HU) and Gout
4.3. Discussion of the Studies Included in This Review: Bone Loss
4.4. Persistent Hyperparathyroidism
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Pichette, V.; Bonnardeaux, A.; Prudhomme, L.; Gagne, M.; Cardinal, J.; Ouimet, D. Long-term bone loss in kidney transplant recipients: A cross-sectional and longitudinal study. Am. J. Kidney Dis. 1996, 28, 105–114. [Google Scholar] [CrossRef]
- Kart-Koseoglu, H.; Yucel, A.E.; Isiklar, I.; Turker, I.; Akcali, Z.; Haberal, M. Joint pain and arthritis in renal transplant recipients and correlation with cyclosporine therapy. Rheumatol. Int. 2003, 23, 159–162. [Google Scholar] [CrossRef] [PubMed]
- Braun, W.E.; Richmond, B.J.; Protiva, D.A.; Gifford, R.W., Jr.; Straffon, R.A. The incidence and management of osteoporosis, gout, and avascular necrosis in recipients of renal allografts functioning more than 20 years (level 5A) treated with prednisone and azathioprine. Transpl. Proc. 1999, 31, 1366–1369. [Google Scholar] [CrossRef]
- Mazzali, M. Uric acid and transplantation. Semin. Nephrol. 2005, 25, 50–55. [Google Scholar] [CrossRef]
- Ducloux, D.; Schuller, V.; Bresson-Vautrin, C.; Chalopin, J.M. Colchicine myopathy in renal transplant recipients on cyclosporin. Nephrol. Dial. Transpl. 1997, 12, 2389–2392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goffin, E.; vande Berg, B.; Pirson, Y.; Malghem, J.; Maldague, B.; van Ypersele de Strihou, C. Epiphyseal impaction as a cause of severe osteoarticular pain of lower limbs after renal transplantation. Kidney Int. 1993, 44, 98–106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grotz, W.H.; Breitenfeldt, M.K.; Braune, S.W.; Allmann, K.H.; Krause, T.M.; Rump, J.A.; Schollmeyer, P.J. Calcineurin-inhibitor induced pain syndrome (CIPS): A severe disabling complication after organ transplantation. Transpl Int. 2001, 14, 16–23. [Google Scholar] [CrossRef]
- Jagose, J.T.; Bailey, R.R.; Hughes, T.H. Acute bone-marrow oedema in cyclosporin-treated renal transplant recipients. QJM 1997, 90, 359–366. [Google Scholar] [CrossRef] [Green Version]
- Julian, B.A.; Quarles, L.D.; Niemann, K.M. Musculoskeletal complications after renal transplantation: Pathogenesis and treatment. Am. J. Kidney Dis. 1992, 19, 99–120. [Google Scholar] [CrossRef]
- Kubo, T.; Fujioka, M.; Yamazoe, S.; Yoshimura, N.; Oka, T.; Ushijima, Y.; Hasegawa, Y.; Hirasawa, Y. Relationship between steroid dosage and osteonecrosis of the femoral head after renal transplantation as measured by magnetic resonance imaging. Transplant Proc. 1998, 30, 3039–3040. [Google Scholar] [CrossRef]
- el-Husseini, A.A.; el-Agroudy, A.E.; Sobh, M.A.; Ghoneim, M.A. Bone loss in pediatric renal transplant recipients. Nefrologia 2003, 23 (Suppl. 2), 131–134. [Google Scholar]
- el-Husseini, A.A.; el-Agroudy, A.E.; Wafa, E.W.; Mohsen, T.; Sobh, M.A.; Ghoneim, M.A. Bone mineral density in live related kidney transplant children and adolescents. Int. Urol. Nephrol. 2004, 36, 95–100. [Google Scholar] [CrossRef] [PubMed]
- Chadha, Y.; Brahme, S.K.; Huang, B.K.; Chang, E.Y. Calcineurin-inhibitor induced pain syndrome-Magnetic resonance imaging and scintigraphic findings illustrated through two cases. Clin. Imaging 2019, 53, 174–178. [Google Scholar] [CrossRef]
- Lucas, V.P.; Ponge, T.D.; Plougastel-Lucas, M.L.; Glemain, P.; Hourmant, M.; Soulillou, J.P. Musculoskeletal pain in renal-transplant recipients. N. Engl. J. Med. 1991, 325, 1449–1450. [Google Scholar] [CrossRef] [PubMed]
- Naredo Sanchez, E.; Balsa Criado, A.; Sanz Guajardo, A.; Pantoja Zarza, L.; Martin Mola, E.; Gijon Banos, J. Leg bone pain syndrome due to cyclosporine in a renal transplant patient. Clin. Exp. Rheumatol. 1994, 12, 653–656. [Google Scholar]
- Goffin, E.; Pirson, Y.; Vande Berg, B.; van Ypersele de Strihou, C. Distal lower limb bone pain after renal transplantation. Transplantation 1996, 61, 1426–1428. [Google Scholar] [CrossRef] [PubMed]
- Goffin, E.; Vande Berg, B.; Devogelaer, J.P.; Pochet, J.M.; De Meyer, M.; Squifflet, J.P.; Pirson, Y. Post-renal transplant syndrome of transient lower limb joint pain: Description under a tacrolimus-based immunosuppression. Clin. Nephrol. 2003, 59, 98–105. [Google Scholar] [CrossRef]
- Puig, I.M.J.M.; Martinez-Miralles, E.; Perich, X.; Lloveras, J.; Mir, M.; Inigo, V.; Barbosa, F.; Orfila, A.; Masramon, J. Reflex sympathetic dystrophy syndrome of the lower limbs in a renal transplant patient treated with tacrolimus. Transplantation 2000, 70, 210–211. [Google Scholar]
- Ebeling, P.R. Approach to the patient with transplantation-related bone loss. J. Clin. Endocrinol. Metab. 2009, 94, 1483–1490. [Google Scholar] [CrossRef] [Green Version]
- Sheta, M.; Riad, S.; Deepak, U.; Issa, N.; Birkenbach, M.; Ibrahim, H.N.; Kukla, A. Costimulation pathway blockade in kidney transplant recipients with de-novo rheumatoid arthritis. Clin. Nephrol. Case Stud. 2017, 5, 16–19. [Google Scholar] [CrossRef] [Green Version]
- Brumby, C.; Huang, L.; Lee, D.; McMahon, L. Acute polyarthritis immediately after kidney transplantation: A medication-induced rheumatoid arthritis flare? Nephrology (Carlton) 2014, 19 (Suppl. 1), 2–5. [Google Scholar] [CrossRef] [PubMed]
- Clive, D.M. Renal transplant-associated hyperuricemia and gout. J. Am. Soc. Nephrol. 2000, 11, 974–979. [Google Scholar] [CrossRef] [PubMed]
- Bose, B.; Badve, S.V.; Hiremath, S.S.; Boudville, N.; Brown, F.G.; Cass, A.; de Zoysa, J.R.; Fassett, R.G.; Faull, R.; Harris, D.C.; et al. Effects of uric acid-lowering therapy on renal outcomes: A systematic review and meta-analysis. Nephrol. Dial. Transpl. 2014, 29, 406–413. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stamp, L.K.; Chapman, P.T. Gout and organ transplantation. Curr. Rheumatol. Rep. 2012, 14, 165–172. [Google Scholar] [CrossRef]
- Bellomo, G. Asymptomatic hyperuricemia following renal transplantation. World J. Nephrol. 2015, 4, 324–329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nikkel, L.E.; Mohan, S.; Zhang, A.; McMahon, D.J.; Boutroy, S.; Dube, G.; Tanriover, B.; Cohen, D.; Ratner, L.; Hollenbeak, C.S.; et al. Reduced fracture risk with early corticosteroid withdrawal after kidney transplant. Am. J. Transplant. 2012, 12, 649–659. [Google Scholar] [CrossRef] [Green Version]
- Omidvar, B.; Ghorbani, A.; Shahbazian, H.; Beladi Mousavi, S.S.; Shariat Nabavi, S.J.; Alasti, M. Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation. Iran J. Kidney Dis. 2011, 5, 420–424. [Google Scholar]
- Nakamura, M.; Tanaka, K.; Marui, Y.; Tomikawa, S. Clinicopathological analysis of persistent hypercalcemia and hyperparathyroidism after kidney transplantation in long-term dialysis patients. Ther. Apher. Dial. 2013, 17, 551–556. [Google Scholar] [CrossRef]
- Taweesedt, P.T.; Disthabanchong, S. Mineral and bone disorder after kidney transplantation. World J. Transpl. 2015, 5, 231–242. [Google Scholar] [CrossRef] [Green Version]
- Iyer, S.P.; Nikkel, L.E.; Nishiyama, K.K.; Dworakowski, E.; Cremers, S.; Zhang, C.; McMahon, D.J.; Boutroy, S.; Liu, X.S.; Ratner, L.E.; et al. Kidney transplantation with early corticosteroid withdrawal: Paradoxical effects at the central and peripheral skeleton. J. Am. Soc. Nephrol. 2014, 25, 1331–1341. [Google Scholar] [CrossRef] [Green Version]
- Coates, P.T.; Tie, M.; Russ, G.R.; Mathew, T.H. Transient bone marrow edema in renal transplantation: A distinct post-transplantation syndrome with a characteristic MRI appearance. Am. J. Transpl. 2002, 2, 467–470. [Google Scholar] [CrossRef] [PubMed]
- Franco, M.; Blaimont, A.; Albano, L.; Bendini, C.; Cassuto, E.; Jaeger, P. Tacrolimus pain syndrome in renal transplant patients: Report of two cases. Jt. Bone Spine 2004, 71, 157–159. [Google Scholar] [CrossRef]
- Collini, A.; De Bartolomeis, C.; Barni, R.; Ruggieri, G.; Bernini, M.; Carmellini, M. Calcineurin-inhibitor induced pain syndrome after organ transplantation. Kidney Int. 2006, 70, 1367–1370. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tillmann, F.P.; Jager, M.; Blondin, D.; Oels, M.; Rump, L.C.; Grabensee, B.; Hetzel, G.R. Post-transplant distal limb syndrome: Clinical diagnosis and long-term outcome in 37 renal transplant recipients. Transpl. Int. 2008, 21, 547–553. [Google Scholar] [CrossRef]
- Abbott, K.C.; Kimmel, P.L.; Dharnidharka, V.; Oglesby, R.J.; Agodoa, L.Y.; Caillard, S. New-onset gout after kidney transplantation: Incidence, risk factors and implications. Transplantation 2005, 80, 1383–1391. [Google Scholar] [CrossRef] [PubMed]
- Numakura, K.; Satoh, S.; Tsuchiya, N.; Saito, M.; Maita, S.; Obara, T.; Tsuruta, H.; Inoue, T.; Narita, S.; Horikawa, Y.; et al. Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival. Transplantation 2012, 94, 145–151. [Google Scholar] [CrossRef]
- Malheiro, J.; Almeida, M.; Fonseca, I.; Martins, L.S.; Pedroso, S.; Dias, L.; Henriques, A.C.; Cabrita, A. Hyperuricemia in adult renal allograft recipients: Prevalence and predictors. Transpl. Proc. 2012, 44, 2369–2372. [Google Scholar] [CrossRef]
- Weng, S.C.; Shu, K.H.; Tarng, D.C.; Cheng, C.H.; Chen, C.H.; Yu, T.M.; Chuang, Y.W.; Huang, S.T.; Wu, M.J. Uric acid is highly associated with kidney allograft survival in a time-varying analysis. Transpl. Proc. 2014, 46, 505–510. [Google Scholar] [CrossRef]
- Kimura-Hayama, E.; Criales-Vera, S.; Nicolaou, S.; Betanzos, J.L.; Rivera, Y.; Alberu, J.; Rull-Gabayet, M.; Hernandez-Molina, G. A pilot study on dual-energy computed tomography for detection of urate deposits in renal transplant patients with asymptomatic hyperuricemia. J. Clin. Rheumatol. 2014, 20, 306–309. [Google Scholar] [CrossRef]
- Brigham, M.D.; Radeck, L.P.; Mendonca, C.M.; Lang, I.; Li, J.W.; Kent, J.D.; LaMoreaux, B.; Mandell, B.F.; Johnson, R.J. Gout Severity in Recipients of Kidney Transplant. Transpl. Proc. 2019, 51, 1816–1821. [Google Scholar] [CrossRef]
- Folkmane, I.; Tzivian, L.; Folkmane, E.; Valdmane, E.; Kuzema, V.; Petersons, A. Predictors of Hyperuricemia after Kidney Transplantation: Association with Graft Function. Medicina 2020, 56, 95. [Google Scholar] [CrossRef] [Green Version]
- Monier-Faugere, M.C.; Mawad, H.; Qi, Q.; Friedler, R.M.; Malluche, H.H. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J. Am. Soc. Nephrol. 2000, 11, 1093–1099. [Google Scholar] [CrossRef] [PubMed]
- Cayco, A.V.; Wysolmerski, J.; Simpson, C.; Mitnick, M.A.; Gundberg, C.; Kliger, A.; Lorber, M.; Silver, D.; Basadonna, G.; Friedman, A.; et al. Posttransplant bone disease: Evidence for a high bone resorption state. Transplantation 2000, 70, 1722–1728. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Casez, J.P.; Lippuner, K.; Horber, F.F.; Montandon, A.; Jaeger, P. Changes in bone mineral density over 18 months following kidney transplantation: The respective roles of prednisone and parathyroid hormone. Nephrol. Dial. Transpl. 2002, 17, 1318–1326. [Google Scholar] [CrossRef] [Green Version]
- Ulivieri, F.M.; Piodi, L.P.; Aroldi, A.; Cesana, B.M. Effect of kidney transplantation on bone mass and body composition in males. Transplantation 2002, 73, 612–615. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Toro, J.; Gentil, M.A.; Garcia, R.; Alvarez, R.; Valdivia, M.A.; Roncero, F.G.; Pereira, P.; Algarra, G.; Mateos, J. Osteoarticular pain and bone mineral density in renal transplantation. Transpl. Proc. 2003, 35, 1769–1771. [Google Scholar] [CrossRef]
- Inoue, S.; Horii, M.; Asano, T.; Fujioka, M.; Ogura, T.; Shibatani, M.; Kim, W.C.; Nakagawa, M.; Tanaka, T.; Hirota, Y.; et al. Risk factors for nontraumatic osteonecrosis of the femoral head after renal transplantation. J. Orthop. Sci. 2003, 8, 751–756. [Google Scholar] [CrossRef] [PubMed]
- El-Agroudy, A.E.; El-Husseini, A.A.; El-Sayed, M.; Ghoneim, M.A. Preventing bone loss in renal transplant recipients with vitamin D. J. Am. Soc. Nephrol. 2003, 14, 2975–2979. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Demant, A.W.; Kocovic, L.; Henschkowski, J.; Siebenrock, K.A.; Ferrari, P.; Steinbach, L.S.; Anderson, S.E. Hip pain in renal transplant recipients: Symptomatic gluteus minimus and gluteus medius tendon abnormality as an alternative MRI diagnosis to avascular necrosis. AJR Am J Roentgenol 2007, 188, 515–519. [Google Scholar] [CrossRef] [PubMed]
- Atallah, A.M.; Farag, S.M.; Senna, M.K.; Ghoneim, M.A. Musculoskeletal affections among kidney recipients: Prevalence and risk predictors. Rheumatol. Int. 2008, 28, 1085–1090. [Google Scholar] [CrossRef] [PubMed]
- Kawarazaki, H.; Shibagaki, Y.; Fukumoto, S.; Kido, R.; Ando, K.; Nakajima, I.; Fuchinoue, S.; Fujita, T.; Fukagawa, M.; Teraoka, S. Natural history of mineral and bone disorders after living-donor kidney transplantation: A one-year prospective observational study. Ther. Apher. Dial. 2011, 15, 481–487. [Google Scholar] [CrossRef] [PubMed]
- Amin, T.; Coates, P.T.; Barbara, J.; Hakendorf, P.; Karim, N. Prevalence of Hypercalcaemia in a Renal Transplant Population: A Single Centre Study. Int. J. Nephrol. 2016, 2016, 7126290. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elder, G.J. From marrow oedema to osteonecrosis: Common paths in the development of post-transplant bone pain. Nephrology (Carlton) 2006, 11, 560–567. [Google Scholar] [CrossRef] [PubMed]
- Gurin, L.; Gohh, R.; Evangelista, P. Pain syndrome with stress fractures in transplanted patients treated with calcineurin inhibitors. Clin. Kidney J. 2012, 5, 13–16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kahan, B.D.; Flechner, S.M.; Lorber, M.I.; Golden, D.; Conley, S.; Van Buren, C.T. Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation 1987, 43, 197–204. [Google Scholar] [CrossRef] [PubMed]
- West, C.; Carpenter, B.J.; Hakala, T.R. The incidence of gout in renal transplant recipients. Am. J. Kidney Dis. 1987, 10, 369–372. [Google Scholar] [CrossRef]
- Gores, P.F.; Fryd, D.S.; Sutherland, D.E.; Najarian, J.S.; Simmons, R.L. Hyperuricemia after renal transplantation. Am. J. Surg. 1988, 156, 397–400. [Google Scholar] [CrossRef]
- Lin, H.Y.; Rocher, L.L.; McQuillan, M.A.; Schmaltz, S.; Palella, T.D.; Fox, I.H. Cyclosporine-induced hyperuricemia and gout. N. Engl. J. Med. 1989, 321, 287–292. [Google Scholar] [CrossRef]
- Ahn, K.J.; Kim, Y.S.; Lee, H.C.; Park, K.; Huh, K.B. Cyclosporine-induced hyperuricemia after renal transplant: Clinical characteristics and mechanisms. Transpl. Proc. 1992, 24, 1391–1392. [Google Scholar]
- Delaney, V.; Sumrani, N.; Daskalakis, P.; Hong, J.H.; Sommer, B.G. Hyperuricemia and gout in renal allograft recipients. Transpl. Proc. 1992, 24, 1773–1774. [Google Scholar]
- Ben Hmida, M.; Hachicha, J.; Bahloul, Z.; Kaddour, N.; Kharrat, M.; Jarraya, F.; Jarraya, A. Cyclosporine-induced hyperuricemia and gout in renal transplants. Transpl. Proc. 1995, 27, 2722–2724. [Google Scholar]
- Shibolet, O.; Elinav, E.; Ilan, Y.; Safadi, R.; Ashur, Y.; Eid, A.; Zamir, G.; Fridlander, M.; Bdolah-Abram, T.; Shouval, D.; et al. Reduced incidence of hyperuricemia, gout, and renal failure following liver transplantation in comparison to heart transplantation: A long-term follow-up study. Transplantation 2004, 77, 1576–1580. [Google Scholar] [CrossRef]
- Boots, J.M.; van Duijnhoven, E.M.; Christiaans, M.H.; Nieman, F.H.; van Suylen, R.J.; van Hooff, J.P. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl. Int. 2001, 14, 370–383. [Google Scholar] [CrossRef] [PubMed]
- Venkat Raman, G.; Sharman, V.L.; Lee, H.A. Azathioprine and allopurinol: A potentially dangerous combination. J. Int. Med. 1990, 228, 69–71. [Google Scholar] [CrossRef]
- Dalbeth, N.; House, M.E.; Horne, A.; Taylor, W.J. Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout. BMC Musculoskelet. Disord. 2013, 14, 363. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Canalis, E. Mechanisms of glucocorticoid-induced osteoporosis. Curr. Opin. Rheumatol. 2003, 15, 454–457. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Horber, F.F.; Casez, J.P.; Steiger, U.; Czerniak, A.; Montandon, A.; Jaeger, P. Changes in bone mass early after kidney transplantation. J. Bone Miner. Res. 1994, 9, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Kalantar-Zadeh, K.; Molnar, M.Z.; Kovesdy, C.P.; Mucsi, I.; Bunnapradist, S. Management of mineral and bone disorder after kidney transplantation. Curr. Opin. Nephrol. Hypertens. 2012, 21, 389–403. [Google Scholar] [CrossRef]
- Canalis, E.; Mazziotti, G.; Giustina, A.; Bilezikian, J.P. Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. Osteoporos. Int. 2007, 18, 1319–1328. [Google Scholar] [CrossRef]
- Nisbeth, U.; Lindh, E.; Ljunghall, S.; Backman, U.; Fellstrom, B. Fracture frequency after kidney transplantation. Transpl. Proc. 1994, 26, 1764. [Google Scholar]
- Torregrosa, J.V. Immunosuppression and bone loss after transplantation. Transpl. Proc. 2001, 33, 3665–3667. [Google Scholar] [CrossRef]
- Torregrosa, J.V.; Campistol, J.M.; Montesinos, M.; Fenollosa, B.; Pons, F.; Martinez de Osaba, M.J.; Oppenheimer, F. Factors involved in the loss of bone mineral density after renal transplantation. Transpl. Proc. 1995, 27, 2224–2225. [Google Scholar]
- Ellis, E.N.; Floyd-Gimon, D.M.; Berry, P.L.; Wells, T.G.; Seibert, J.; Belsha, C. Risk factors for bone mineral density loss in pediatric renal transplant patients. Pediatr. Transpl. 2000, 4, 146–150. [Google Scholar] [CrossRef]
- Ellis, E.N.; Martz, K.; Talley, L.; Ilyas, M.; Pennington, K.L.; Blaszak, R.T. Factors related to long-term renal transplant function in children. Pediatr. Nephrol. 2008, 23, 1149–1155. [Google Scholar] [CrossRef]
- Aroldi, A.; Tarantino, A.; Montagnino, G.; Cesana, B.; Cocucci, C.; Ponticelli, C. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: A prospective study. Transplantation 1997, 63, 380–386. [Google Scholar] [CrossRef] [PubMed]
- Evenepoel, P.; Behets, G.J.; Viaene, L.; D’Haese, P.C. Bone histomorphometry in de novo renal transplant recipients indicates a further decline in bone resorption 1 year posttransplantation. Kidney Int. 2017, 91, 469–476. [Google Scholar] [CrossRef]
- Farmer, C.K.; Hampson, G.; Abbs, I.C.; Hilton, R.M.; Koffman, C.G.; Fogelman, I.; Sacks, S.H. Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density. Am. J. Transpl. 2006, 6, 2929–2936. [Google Scholar] [CrossRef]
- Canalis, E.; Delany, A.M. Mechanisms of glucocorticoid action in bone. Ann. N. Y. Acad. Sci. 2002, 966, 73–81. [Google Scholar] [CrossRef] [PubMed]
- El-Agroudy, A.E.; El-Husseini, A.A.; El-Sayed, M.; Mohsen, T.; Ghoneim, M.A. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int. 2005, 67, 2039–2045. [Google Scholar] [CrossRef] [Green Version]
- Damasiewicz, M.J.; Ebeling, P.R. Management of mineral and bone disorders in renal transplant recipients. Nephrology (Carlton) 2017, 22 (Suppl. 2), 65–69. [Google Scholar] [CrossRef] [Green Version]
- Wolf, M.; Weir, M.R.; Kopyt, N.; Mannon, R.B.; Von Visger, J.; Deng, H.; Yue, S.; Vincenti, F. A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation 2016, 100, 184–193. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kawarazaki, H.; Shibagaki, Y.; Fukumoto, S.; Kido, R.; Nakajima, I.; Fuchinoue, S.; Fujita, T.; Fukagawa, M.; Teraoka, S. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: A 1-year prospective observational study. Nephrol. Dial. Transpl. 2011, 26, 2691–2695. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cruzado, J.M.; Lauzurica, R.; Pascual, J.; Marcen, R.; Moreso, F.; Gutierrez-Dalmau, A.; Andres, A.; Hernandez, D.; Torres, A.; Beneyto, M.I.; et al. Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients. Kidney Int. Rep. 2018, 3, 122–132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perrin, P.; Caillard, S.; Javier, R.M.; Braun, L.; Heibel, F.; Borni-Duval, C.; Muller, C.; Olagne, J.; Moulin, B. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am. J. Transpl. 2013, 13, 2653–2663. [Google Scholar] [CrossRef] [PubMed]
- Bonarek, H.; Merville, P.; Bonarek, M.; Moreau, K.; Morel, D.; Aparicio, M.; Potaux, L. Improvement of parathyroid function after kidney transplantation: Effect on parathyroid functional mass. Transpl. Proc. 2000, 32, 401–403. [Google Scholar] [CrossRef]
- Moreno, P.; Coloma, A.; Torregrosa, J.V.; Montero, N.; Francos, J.; Codina, S.; Manonelles, A.; Bestard, O.; Garcia-Barrasa, A.; Melilli, E.; et al. Long-term results of a randomized study comparing parathyroidectomy with cinacalcet for treating tertiary hyperparathyroidism. Clin. Transpl. 2020, 34, e13988. [Google Scholar] [CrossRef]
- Evenepoel, P.; Van Den Bergh, B.; Naesens, M.; De Jonge, H.; Bammens, B.; Claes, K.; Kuypers, D.; Vanrenterghem, Y. Calcium metabolism in the early posttransplantation period. Clin. J. Am.Soc. Nephrol. 2009, 4, 665–672. [Google Scholar] [CrossRef] [Green Version]
- Messa, P.; Alfieri, C.; Rastaldi, M.P. Recent insights into vitamin D and its receptor. J. Nephrol. 2011, 24 (Suppl. 18), S30–S37. [Google Scholar] [CrossRef]
SN | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
---|---|---|---|---|---|---|---|
Author et al. year | Grotz WH et al. 2001 [7] | Coates PT et al. 2002 [31] | Goffin E et al. 2003 [17] | Kart-Koseoglu H et al. 2003 [2] | Franco M et al. 2004 [32] | Collini A et al. 2006 [33] | Tillmann F. et al. 2008 [34] |
Country | Germany | Australia | Belgium | Turkey | France | Italy | Germany |
Type of study (MC/SC) | Prospective cohort study SC | Prospective cohort study SC | Prospective cohort study SC | Retrospective cohort study SC | Prospective cohort study SC | Retrospective cohort study SC | Retrospective cohort study SC |
Objective | To investigate CIPS in the feet of 8 out of 637 KTxR using bone scan and MRI | To investigate MRI findings in 4 out of 134 KTxR who developed severe bilateral knee pain | To investigate the occurrence of the post-KTx syndrome in KTxR given a tacrolimus-based therapy | To determine the prevalence of joint pain and arthritis in KTxR | To investigate tac pain syndrome in 2 out of 90 KTxR on Tac over 3 years. | To investigate CIPS after KTx in 2 out of 243 pts | To determine the clinical diagnosis and long-term outcome of BPS of lower limbs in 37 out of 639 KTxR |
T No of KTxR pts F: (%) M: (%) | 8 F: 2 (25%) M: 6 (75%) | 134 F: 2 (1.49%) M: 2 (1.49%) | 86 F: 2 (40%) M: 3 (60%) | 82 F: 26 (31.7%) M: 56 (68.2%) | 2 F: 1 (50%) M: 1 (50%) | 243 F: 0 M: 2 (0.82%) | 37 F: NA M: NA |
Musculoskeletal (MSK) manifestations Prevalence, No. (%) Time after KTx, M ± SD (range); months | CIPS 3 (1.25) NA (1–18) | BPS 4 (2.98) 1 | BPS 5/(6) 6 | BPS 17 (20.7) BMD done 51/82 (spine: osteopenia 39.2%, osteoporosis 31.4% and femur: osteopenia 47.1%, osteoporosis 31.4%) 12 | CIPS 2 (2.2) NA (1–3) | CIPS 2 (0.82) NA (1–6) | BPS 37 (5.8) 5.8 ± 4.8 (1–30) |
Age M ± SD years. (range) years. | NA (26–52) | 46.75 (40–50) | 46.6 (30–58) | 18.41 ± 15.94 (12–56) | 57 years (F) 49 years (M) | 42 and 49 | 50.4 ± 10.9 (30.6–66.8) |
MDD/DD Study period | NA 7 years | NA 3 months | 22 months 10 moths | 14 years 1 year | 3 years 13 years | NA 15 years | 5.1 ± 3.1 months 8 years |
Type of Donor transplant | NA | Cadaveric | Cadaveric | 18 cadaveric 60 first-degree relative 4 spouse | NA | Deceased | 28 cadaveric 9 living |
Causes of ESRD | IgA N, NPS, APKD, GS, Mesanigo-PGN, Reflux N Membrano-PGN, | -IgA Nephropathy -AN | HTN, PKD, NAS, CP, Unknown. | NA | NA | NA | NA |
Pretransplant dialysis No. (duration in months) | 3 PD (3–120) 5 HD (7–168.) | NA | 1 PD (45) 2–5 HD (8–45) | NA 18 | 1 (28) 1 (29) | NA | NA |
Immunosuppressive Therapy | CyA Tac CS MMF Aza ATG | CyA CS MMF Sirolimus | Tac CS MMF | CyA CS Aza | Tac CS MMF Aza | CyA Tac CS MMF Basiliximab Everolimus | CyA Tac MMF |
Other therapy | Ibuprofen, Morphine, Alpha-lipoic, Carbamazepine, CCB Bisphosphonate, | NA | PCM | NA | Calcium Vit D Salmon Calcitonin Pamidronate | CCB | CCB |
Renal function (Cr.; mg/dL); Mean (range) | NA | NA | 5 ESRD 1.45–2.95 | NA | NA | NA | 1.79 ± 0.68 (0.80–4.40) |
Graft (rejection) | NA | NA | 1 Acute rejection 2 Chronic rejection | 9 acute rejection | NA | 1 acute rejection | NA |
Co-morbidity No. (%) | NA | SLE | HTN | HCV Ab positive: 15 (18.3%) | NA | DLP: 1 (50%) | NA |
SN | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
---|---|---|---|---|---|---|---|
Author et al., Year | Abbott K et al. 2005 [35] | Numakura K et al. 2012 [36] | Malheiro J et al. 2012 [37] | Weng S.C et al. 2014 [38] | Kimura-Hayama E et al. 2014 [39] | Brigham M et al. 2019 [40] | Folkmane I et al. 2020 [41] |
Country | United States | Japan | Portugal | Taiwan | Mexico | United States | Latvia |
Type of study (MC/SC) | Retrospective cohort study MC | Prospective cohort study SC | Retrospective cohort study SC | Prospective cohort study MC | Prospective cohort study SC | Retrospective cohort study MC | Retrospective cohort study SC |
Total No of KTxR (%) F: (%) M: (%) | 28,942 (97.7%) F: NA M: NA | 121 HU = 46 F: 8 (17.3%) M: 38 (82.6%) NU = 75 F: 37 (49.3) M: 38 (50.6%) | 302 F: 119 (39.4%) M: 183 (60.5%) | 880 HU = 389 F: 144 (37%) M: 245 (62.9%) NU: 491 F: 268 (54.5%) M: 223 (45.4%) | 27 F: 20 (74%) M: 17 (63%) | 312 (25 with Gout) F: 7 (28%) M: 18 (72%) | 144 F: 111 (77%) M: 33 (22.9%) |
Musculoskeletal (MSK) manifestations No. (%) Time after KTx, months | Gout: 1593 (5.5%) 7.6% (Cumulative at 3 years) 36 | HU 46 (38%) 12 | HU: 127 (42.1%) 90 (2.3–14.2) | HU: 389 (44.2%) Gouty: 22.37% 1–3 | Gout (selected 27) Prevalence of MSU deposition is 0.03% 0.5–16.8 years. | Gout: 25 (8.0%) 12 months | HU: 61 (42.4%) ≥12 months |
Age; M ± SD (range) years. | 45.4 ± 14.6 (NA) | 44.9 (20–78) | 49.6 ± 13.4 (NA) | HU: 50.03 ± 12.07 (NA) NU: 47.59 ± 12.57 (NA) | 44.7 ± 12.9 (NA) | 55.1 ± 14.1 (NA) | 46.6 ± 13.9 (NA) |
MDD/DD Study period/years | NA 5 years | NA 5 years | NA 27 years | 43.3 ± 26.3 months 14 years | 3.2 years. 7 years. | NA 1 year | NA 3 years |
Type of Donor transplant | Deceased | Allograft | Allograft | NA | NA | NA | NA |
Total No Pts with ESRD Pts No (%) for diseases as causes of ESRD | 59,077 ESRD 7145 (28.2%) DM 5312 (21.4) HTN 1262 (7.6) IHD 1872 (11.3) HF | 121 ESRD: 70 IgA Nephropathy, 10 DN, 8 PKD, 4 Lupus nephritis, NS Alports syndrome, RN, 1 WG, 4 pregnancy toxicosis | 302 ESRD | 880 ESRD | 27 ESRD | 312 ESRD | 144 ESRD: 17 PKD |
Pretransplant dialysis No. of patients/% (Periods in months/years.) | NA | NA 56.3 (0–420) months | NA | HD: 29.56% | 1 (0.5–10.6) years | NA | NA |
Immunosuppressive Therapy used | CyA Tac MMF Aza Sirolimus | Tac CS MMF Basiliximab | CyA Tac CS MMF Aza Sirolimus | CyA Tac CS MMF Aza | CyA Tac MMF Aza Sirolimus | NA | CyA Tac CS MMF |
Other therapy | NA | Allopurinol, MP pulse, Furosemide, Beta-blocker | ACEi | Allopurinol, Dithiazide, Benzbromarone, Aspirin | Allopurinol | Allopurinol, Febuxostat | ACEi, ARBs, Diuretics, Allopurinol Febuxostat |
Renal function: mean Cr/CrC ± SD (mg/dl) eGFR (mL/1.73 m) | Cr. 1.8 ± 20.8 eGFR at 1 year post KTx < 44 | NA eGFR: 47.6 ± 11.8 | NA eGFR: 51.9 ± 18.46 | Cr.: 2.96 ± 3.20 NA | CrC: 66 (7–119) NA | NA eGFR 45–59 mL/min: 65% eGFR < 15 mL/min: 6% | NA eGFT > 60: 19 (35.2%) at 3 years eGFR < 60: NA |
Graft rejection Acute or chronic | Chronic (with the first year) | 91.6% 5-year graft survival rate and decreased thereafter | Chronic with 43 (14.2%) pts had 2nd graft | 60.47% poor graft survival | NA | NA | NA |
Co-morbidity No. (%) * = with new onset gout | DM: 237 (3.5%)* HTN: 389 (7.3%)* IHD: 85 (6.7%)* HF: 117 (6.3)* | DM: 33 HTN: 7 DLP: 26 CMV: 10 | HTN 246 (81.5%) DLP 208 (68.9%) DM 41 (13.6%) | HTN (92.29%), DM (140 (35.99), CVD (56 (14.40), DLP (62.98%), HCV, HBV (24.42%), TB, CMV, Shingles | HTN 24 (88.9%) DM 4 (14.8%) DLP 21 (77.8%) | NA | HTN: 51 (83.6%) DM: 7 (11.5%) DLP: 38 (62.3%) |
SN | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Author et al., Year | Monier-Faugere M et al. 2000 [42] | Cayco A et al. 2000 [43] | Casez JP et al. 2002 [44] | Ulivieri FM et al. 2002 [45] | Toro J et al. 2003 [46] | Inoue S et al. 2003 [47] | El-Agroudy A et al. 2003 [48] | Demant AW et al. 2007 [49] | Atallah A M et al. 2008 [50] | Kawarazaki H et al. 2011 [51] | Nakamura M et al. 2013 [28] | Amin T et al. 2016 [52] |
Country | USA | USA | France | Italy | Spain | Japan | Egypt | Switzerland | Egypt | Japan | Japan | Australia |
Type of study (MC/SC) | Prospective cohort study SC | Prospective cohort study SC | Prospective cohort study SC | Prospective cohort study SC | Prospective cohort study SC | Prospective cohort study SC | Prospective cohort study SC | Prospective cohort study SC | Prospective cohort study SC | Prospective cohort study SC | Prospective cohort study MC | Retrospective cohort study SC |
Objective | To investigate the prevalence of bone disease in 57 out of 120 pts post KTx | To assess the prevalence of osteoporosis after one yr. post-KTx | To investigate the role of PDN and PTH in changing BMD following KTx | To investigate the effect of KT on bone mass and body composition in males | To evaluate the BMD and osteoarticular pain in adult patients who have undergone KTx | To investigate RFs for osteonecrosis of the femoral head in KTx among 18 out of 287 | To investigate the effect of treatment with active Vitamin D on the prevention of Post KTx bone loss | To evaluate the diagnosis on MRI and radiography of KTxR with hip pain suspicious for AVN and symptomatic gluteal tendons abnormality | To determine Musculoskeletal affections (MSK) among KTxR and find possible risk predictors. | To show the natural history of mineral metabolism in post-KTxR and to clarify RF of persistent HC and hypo-phosphatemia at 12 mo after KTx | To investigate persistent HC and HPT post KTx in long-term dialysis | To determine the prevalence of HC and to evaluate the RFs for post-KTx HC in long-term KTxR |
T No of KTxR pts F: (%) M: (%) | 120 F: 25 (43.8) M: 32 (56.1) | 69 F: 29 (42) M: 40 (58) | 33 F: 19 (57.5) M: 14 (42.4) | 20 F: 0 M: 20 (100) | 123 F: 72(58.5) M: 51(41.4) 32.5% postmenopausal and 26% premenopausal | 18 F: 7 (38.8) M: 11 (61.1) | 40 F: 0 M: 40 | 24 F: 16 (66.6) M: 8(33.3) | 117 95 (81.2%) with MSK symptoms F: 22(23.1%) M: 73 (76.8%) 22 (18.8%) without MSK F: M = 3: 19 | 34 F: 12(35) M: 22(65) | 34 F: 12 (35) M: 22(65) | 679 F: 39 (39) M: 61 (61) |
Musculoskeletal (MSK) manifestations Prevalence, No. (%) Time after KTx M ± SD (range); months | Osteomalacia 57 (52.7) 60.4 ± 11 (6–247) | Osteoporosis and osteopenia 60 (88) Osteoporosis spine or hip 31 (44) Osteopenia 31 (44) >12 | Low BMD (Whole body) 12 (36) 18 | Trabecular bone loss of spine 3 (14.5) pelvis 1 (3.2) 6 | BMD was reduced in 76.2% Osteopenia: 67 (54.8) Premenopausal 25 (37.5) Postmenopausal Men 42 (62.7) Osteoporosis: Premenopausal 16.1%, postmenopausal 50%, men 7.8% >12 | ONF 7.28% (18) 0–12 | Baseline osteopenia 35% at the lumbar spine, 30% at the femoral neck, and 25% at the forearm, whereas osteoporosis occurs at these sites (10%, 15%, and 5%, respectively 6–12 | 33% (8) AVN/ONF 54.1% (13) enthesopathy: Gluteus minimums and Medius tendons abnormality two pts has dual findings 20.8% (5) Normal findings > 6 mo | 95 (81.2) Bone loss: 78 (82.1) Joint pain: 63 (66.3) Skeletal muscle affection: 21 (22.1) Soft tissue affection: 25 (26.3) BPS: 7 (37) 50 (1–242) | HC 21% Persistent hyper-PTH 100% (34) causing persistent hypercalcemia (21%) and hypo-phosphatemia (15%) 12 | HC 47.1% (16) 12 | HC 15% (101) March 2011-June 2011 3 |
Age MA ± SD (range) years | 45 ± 2 (NA) | 45 ± 11.2 (NA) | 46 ± 2 (NA) | 40 (23–64) | 49.3 ± 9.87 (NA) | 34.7 (20.5–56.6) | 31.4 ± 10.1 (18–50) | 57.1 (26–71) | 38.6 ± 11.1 (19.6–56.0) | 50 (36–60) | 53.8 ± 7.9 (NA) | 55± 13 (NA) |
MDD/DD Study period, mo | NA NA | >12 NA | NA 18 | 109 ± 74 NA | NA 1980–2000 | NA 1983–1992 | NA 12 | 180 1998–2002 | NA 2005–2006 | 12 2007–2008 | 162 ± 49 2002–2010 | 480 1971–2011 |
Type of Donor transplant | NA | 41 cadaveric 28 living | NA | Living | Cadaveric | 3 dead 15 living | Living | NA | NA | Living | Deceased | NA |
Causes of ESRD | NA | NA | NA | 34 CGN 16 RN 12 DN 12 PKD | ||||||||
Pretransplant dialysis No. (duration in months) | 51 (36 ± 0.6) 32 HD 19 PD | 1.74 ± 3.03 | HD: 30 PD: 4 (63 ± 12) | HD: NA (23 ± 19) | NA | NA | NA (10.8 ± 5.4) | NA | NA (12) | NA | NA (172.8 ± 51.6) | 65 HD 18 PD |
Immunosuppressive Therapy | CyA CS MMF Aza | CyA Tac CS | CyA CS Aza | CyA CS Aza | NA | CyA Aza | CyA CS | CyA CS | CyA Tac CS Sirolimus | CyA Tac CS MMF | NA | NA |
Other therapy | Diuretics Phosphate supplement | ERT | Phosphate supplements beta blockers CCB | NA | NA | -CS | NA | NA | NA | Active Vitamin D3 Phosphate Binders (Ca-containing) | NA | NA |
Renal function (Cr.;mg/dl); Mean (range) | 1.6 ± 0.1 (0.7–4.3) | 1.4 ± 0.4 | NA | NA | 1.47± 0.8 | NA | 1.4 ± 0.4 | NA | NA | NA | eGFR 47.2 mL/min | eGFR 30–60 mL/min |
Graft (rejection) | NA | NA | 13 AR | NA | NA | NA | NA | NA | 15 CR | NA | NA | NA |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hassan, A.B.; Ghalib, K.W.; Jahrami, H.A.; El-Agroudy, A.E. Prevalence of Musculoskeletal Manifestations in Adult Kidney Transplant’s Recipients: A Systematic Review. Medicina 2021, 57, 525. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57060525
Hassan AB, Ghalib KW, Jahrami HA, El-Agroudy AE. Prevalence of Musculoskeletal Manifestations in Adult Kidney Transplant’s Recipients: A Systematic Review. Medicina. 2021; 57(6):525. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57060525
Chicago/Turabian StyleHassan, Adla B., Kanz W. Ghalib, Haitham A. Jahrami, and Amgad E. El-Agroudy. 2021. "Prevalence of Musculoskeletal Manifestations in Adult Kidney Transplant’s Recipients: A Systematic Review" Medicina 57, no. 6: 525. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57060525